List of Figures
Figure 1: Global Sales Forecast by Country for Acromegaly and Gigantism in 2019 and 2029
Figure 2: Analysis of the Company Portfolio Gap in Acromegaly and Gigantism During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for Acromegaly/Gigantism During the Forecast Period
Figure 4: Regulation of the Growth Hormone Axis
Figure 5: 7MM, Diagnosed Prevalence of Acromegaly (%), Men and Women, Ages ?15 Years, 2019
Figure 6: 7MM, Diagnosed Prevalence of Gigantism (%), Men and Women, All Ages, 2019
Figure 7: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of Acromegaly
Figure 8: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Gigantism
Figure 9: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Acromegaly and Gigantism with Macroadenoma
Figure 10: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Acromegaly and Gigantism with Diabetes
Figure 11: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Acromegaly and Gigantism with Cardiovascular Disease
Figure 12: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Acromegaly and Gigantism with Hypertension
Figure 13: 7MM, Diagnosed Prevalent Cases of Acromegaly, Both Sexes, Ages ?15 Years, N, 2019
Figure 14: 7MM, Diagnosed Prevalent Cases of Acromegaly by Sex, Ages ?15 Years, N, 2019
Figure 15: 7MM, Diagnosed Prevalent Cases of Acromegaly by Age, Both Sexes, N, 2019
Figure 16: 7MM, Diagnosed Prevalent Cases of Acromegaly with Macroadenoma, Both Sexes, Ages ?15 Years, N, 2019
Figure 17: 7MM, Diagnosed Prevalent Cases of Acromegaly with Comorbidities, Both Sexes, Ages ?15 Years, N, 2019
Figure 18: 7MM, Diagnosed Prevalent Cases of Gigantism, Both Sexes, All Ages, N, 2019
Figure 19: 7MM, Diagnosed Prevalent Cases of Gigantism, by Sex, All Ages, N, 2019
Figure 20: 7MM, Diagnosed Prevalent Cases of Gigantism by Age, Both Sexes, N, 2019
Figure 21: 7MM, Diagnosed Prevalent Cases of Gigantism with Macroadenoma, Both Sexes, All Ages, N, 2019
Figure 22: 7MM, Diagnosed Prevalent Cases of Gigantism with Comorbidities, Both Sexes, All Ages, N, 2019
Figure 23: Unmet Needs and Opportunities in Acromegaly and Gigantism
Figure 24: Overview of the Development Pipeline in Acromegaly and Gigantism
Figure 25: Ongoing Phase II/III Trials for the Pipeline Agents that GlobalData Expects to Be Licensed for Acromegaly and Gigantism in the 7MM, 2019-2029
Figure 26: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for Acromegaly/Gigantism During the Forecast Period
Figure 27: Company Portfolio Gap Analysis in Acromegaly and Gigantism, 2019-2029
Figure 28: Clinical Trials for Acromegaly and Gigantism in the 7MM by Trial Status
Figure 29: Global (7MM) Sales Forecast by Country for Acromegaly and Gigantism in 2019 and 2029
Figure 30: Global (7MM) Sales Forecast by Therapeutic Class for Acromegaly and Gigantism in 2019 and 2029
Figure 31: Global (7MM) Sales Forecast by Individual Drug for Acromegaly and Gigantism in 2019 and 2029
Figure 32: Acromegaly and Gigantism Sales in the US by Drug, 2019 and 2029
Figure 33: Acromegaly and Gigantism Sales in the 5EU by Drug, 2019 and 2029
Figure 34: Acromegaly and Gigantism Sales in Canada by Drug, 2019 and 2029


List of Tables
Table 1: Acromegaly and Gigantism: Key Metrics in the 7MM
Table 2: Metabolic Effects of GH, IGF-1, and Acromegaly
Table 3: Signs and Symptoms of Acromegaly and Gigantism
Table 4: Risk Factors and Comorbidities for Acromegaly and Gigantism
Table 5: Global Consensus Criteria for the Diagnosis and Cure of Acromegaly
Table 6: Commonly Used Treatment Guidelines for Acromegaly
Table 7: Acromegaly and Gigantism Disease Management - US
Table 8: Acromegaly and Gigantism Disease Management - 5EU
Table 9: Acromegaly and Gigantism Disease Management - Canada
Table 10: Marketed Therapies for Acromegaly and Gigantism Across the 7MM.
Table 11: Examples of Primary and Secondary Endpoints in Clinical Trials for Marketed Drugs
Table 12: Comparison of Therapeutic Classes in Development for Acromegaly and Gigantism, 2019-2029
Table 13: Early-Stage Pipeline Agents for Acromegaly, 2020
Table 14: Novartis’ Acromegaly and Gigantism Portfolio Assessment, 2020
Table 15: Ipsen’s Acromegaly and Gigantism Portfolio Assessment, 2020
Table 16: Sun Pharma’s Acromegaly and Gigantism Portfolio Assessment, 2020
Table 17: Pfizer’s Acromegaly and Gigantism Portfolio Assessment, 2020
Table 18: Chiasma’s Acromegaly and Gigantism Portfolio Assessment, 2020
Table 19: Antisense Therapeutics’ Acromegaly and Gigantism Portfolio Assessment, 2020
Table 20: Crinetics’ Acromegaly and Gigantism Portfolio Assessment, 2020
Table 21: Ionis Pharma’s Acromegaly and Gigantism Portfolio Assessment, 2020
Table 22: Camurus’ Acromegaly and Gigantism Portfolio Assessment, 2020
Table 23: Strongbridge Biopharma’s Acromegaly and Gigantism Portfolio Assessment, 2020
Table 24: Enesi Pharma’s Acromegaly and Gigantism Portfolio Assessment, 2020
Table 25: Italfarmaco’s Acromegaly and Gigantism Portfolio Assessment, 2020
Table 26: Acromegaly and Gigantism Market - Global Drivers and Barriers, 2019-2029
Table 27: Key Events Impacting Sales for Acromegaly and Gigantism in the US, 2019-2029
Table 28: Acromegaly and Gigantism Market - Drivers and Barriers in the US, 2019-2029
Table 29: Key Events Impacting Sales for Acromegaly and Gigantism in the 5EU, 2019-2029
Table 30: Acromegaly and Gigantism Market - Drivers and Barriers in the 5EU, 2019-2029
Table 31: Key Events Impacting Sales for Acromegaly and Gigantism in Canada, 2019-2029
Table 32: Acromegaly and Gigantism Market - Drivers and Barriers in Canada, 2019-2029
Table 33: Key Historical and Projected Launch Dates for Acromegaly and Gigantism
Table 34: Key Historical and Projected Patent Expiry Dates for Acromegaly and Gigantism
Table 35: High-Prescribing Physicians (non-KOLs) Surveyed, By Country